ICER recommends top price of $200,000 per year for new bladder cancer drugs

6 November 2020

The Institute for Clinical and Economic Review (ICER) has weighed up the comparative clinical effectiveness and value of two drugs in development for non-muscle invasive bladder cancer (NMIBC) that is unresponsive to Bacillus Calmette-Guerin (BCG) intravesical therapy.

ICER’s evidence report looks at Adstiladrin (nadofaragene firadenovec) from FKD Therapies and FerGene, along with Vicineum (oportuzumab monatox) from Sesen Bio (Nasdaq: SESN), neither of which has yet received approval from the US Food and Drug Administration (FDA).

The report finds that the evidence has significant limitations, and no firm estimate of net health benefit versus best supportive care was able to be determined for either.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK